Literature DB >> 32773139

Quality of life after rectal-preserving treatment of rectal cancer.

Helen J S Jones1, Issam Al-Najami2, Chris Cunningham2.   

Abstract

AIM: Rectal-preserving strategies for managing rectal cancer are becoming more common for selected groups of patients. Oncological outcomes are similar, so long as patients are closely followed, and any local recurrence detected and managed promptly. Functional outcomes are now of increasing importance so patients can be appropriately counselled prior to treatment. We examine functional outcomes in patients managed by multimodal organ-preservation approaches allowing comparison of the full range of strategies.
MATERIALS AND METHODS: Patients attending for surveillance after any of four rectal-preserving treatments for rectal cancer (radiotherapy [RT], local excision [LE], RT then LE or LE then RT) were asked to complete a questionnaire assessing general quality of life and bowel, urinary and sexual function.
RESULTS: 100 patients completed questionnaires: 34 managed by neoadjuvant RT followed by 'watch and wait', 40 by LE, and 26 who had composite treatment (18 LE + RT and eight RT + LE). Questionnaires were completed a median of 10 months (IQ range 6-33) following treatment. The LE only group tended to have better bowel function, while the composite groups fared worse; significant differences were noted in LARS and some bowel symptoms scores.
CONCLUSION: Bowel function appears better after LE alone compared with treatment strategies involving RT, and composite treatments have an additive effect on outcome impairment. Overall quality of life outcomes are good, despite the ongoing requirement for surveillance. As these treatments become more common it is important that patients can be better informed before deciding on a management pathway.
Copyright © 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Functional outcomes; Organ preservation; Quality of life; Rectal cancer

Mesh:

Substances:

Year:  2020        PMID: 32773139     DOI: 10.1016/j.ejso.2020.07.018

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  5 in total

1.  Post-Operative Functional Outcomes in Early Age Onset Rectal Cancer.

Authors: 
Journal:  Front Oncol       Date:  2022-05-30       Impact factor: 5.738

Review 2.  The Prognostic Importance of ctDNA in Rectal Cancer: A Critical Reappraisal.

Authors:  Edina Dizdarevic; Torben Frøstrup Hansen; Anders Jakobsen
Journal:  Cancers (Basel)       Date:  2022-04-30       Impact factor: 6.575

3.  Adoption of Organ Preservation and Surgeon Variability for Patients with Rectal Cancer Does Not Correlate with Worse Survival.

Authors:  Jin K Kim; Hannah Thompson; Rosa M Jimenez-Rodriguez; Fan Wu; Francisco Sanchez-Vega; Garrett M Nash; Jose G Guillem; Philip B Paty; Iris H Wei; Emmanouil P Pappou; Maria Widmar; Martin R Weiser; J Joshua Smith; Julio Garcia-Aguilar
Journal:  Ann Surg Oncol       Date:  2021-10-03       Impact factor: 5.344

4.  [Organ preservation after short-course radiotherapy and transanal endoscopic microsurgery for early-stage rectal cancer (TREC)].

Authors:  Julius Pochhammer; Jürgen Dunst
Journal:  Strahlenther Onkol       Date:  2021-06-04       Impact factor: 3.621

5.  The "Immunoscore" in rectal cancer: could we search quality beyond quantity of life?

Authors:  Amos Kirilovsky; Carine El Sissy; Guy Zeitoun; Florence Marliot; Nacilla Haicheur; Christine Lagorce-Pagès; Julien Taieb; Mehdi Karoui; Petra Custers; Edina Dizdarevic; Soledad Iseas; Torben Frøstrup Hansen; Lars Henrik Jensen; Geerard Beets; Jean Pierre Gérard; Mireia Castillo-Martin; Nuno Figueiredo; Angelita Habr-Gama; Rodrigo Perez; Jérôme Galon; Franck Pagès
Journal:  Oncotarget       Date:  2022-01-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.